Liver Diseases  >>  ViraferonPeg (peginterferon-α-2b)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

13 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ViraferonPeg (peginterferon-α-2b) / Merck (MSD)
NCT00087568: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin

Completed
4
57
US
Ribavirin, peginterferon alfa-2a [Pegasys]
Hoffmann-La Roche
Hepatitis C, Chronic
03/06
03/06
NCT00087607: Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).

Completed
4
385
US
Ribavirin, Copegus, Peginterferon alfa-2b (PEG-Intron), Rebetol, Peginterferon alfa-2a [Pegasys]
Hoffmann-La Roche
Hepatitis C, Chronic
03/06
04/06
NCT00279565 / 2005-000240-82: Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED)

Terminated
4
128
Europe
buprenorphine, methadone, pegylated interferon alfa-2b plus ribavirin
Indivior Inc., AESCA Pharma GmbH
Hepatitis C, Chronic
02/07
02/07
NCT00277862: Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4

Completed
4
280
RoW
Pegylated IFN- alpha 2b, PEG-IFN alpha-2b, PEG-Intron™, Ribavirin, Rebetol, Virin, Ribavrin
Ain Shams University, Schering-Plough, Fulbright, Tempus Labs, International Society for Infectious Diseases
Hepatitis C
03/07
04/07
NCT00351871: Influence of Marker of Insulin Resistance Upon Hepatitis C Virus (HCV) Treatment Responses to PEG Intron and Rebetol Therapy

Completed
4
400
US
PEG-Intron Plus REBETOL
Louisiana State University Health Sciences Center in New Orleans, Schering-Plough
Chronic Hepatitis C
11/07
11/07
NCT00087646: REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy

Completed
4
948
US, Canada, Europe, RoW
Ribavirin, peginterferon alfa-2a [Pegasys]
Hoffmann-La Roche
Hepatitis C, Chronic
05/08
05/08
NCT00202839: Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)

Completed
4
160
NA
PegIntron (peginterferon alfa-2b; SCH 54031), peginterferon alfa-2b; SCH 54031, Ribavirin, SCH 18908
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
07/08
07/08
NCT00687544: Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)

Terminated
4
11
NA
Peginterferon alfa-2b (SCH 054031), PegIntron, Ribavirin (SCH 018908), Rebetol
Merck Sharp & Dohme LLC
Hepatitis C, Chronic, Hepacivirus, HIV Infections
09/08
09/08
NCT00493805 / 2006-000757-21: Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)

Terminated
4
59
NA
Combination of pegylated interferon alfa-2b and ribavirin, (a) SCH 54031, PEG-Intron, (b) SCH 18908, Rebetol
Merck Sharp & Dohme LLC
Hepatitis C, Chronic, Insulin Resistance
10/09
10/09
NCT00686777: Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)

Completed
4
75
NA
Pegylated Interferon alfa-2b, SCH 54031, Ribavirin, SCH 18908
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
12/10
12/10
NCT01405027: Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy

Checkmark ACG 2013: OPTIMAL
Sep 2013 - Sep 2013: ACG 2013: OPTIMAL
Completed
4
197
US
Educational Intervention, Peg-Intron, Pegasys, Victrelis, Pegylated interferon alfa 2B, Pegylated interferon alfa 2A, Boceprevir, Ribavirin, Patient education and management skills training
Chronic Liver Disease Foundation, SCRI Development Innovations, LLC, Merck Sharp & Dohme LLC
Chronic Hepatitis C, Genotype 1
07/14
07/14
NCT01770223 / 2012-002771-33: A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)

Withdrawn
4
0
NA
boceprevir, SCH 503034, PegIFN-2b, Peginterferon alfa-2b, PegIntron, SCH 054031, RBV, Ribavirin, Rebetol
Merck Sharp & Dohme LLC
Hepatitis C
12/15
12/15
NCT01727271: A Study to Compare Efficacy and Safety of Tenofovir Used Alone or in Combination With Pegylated Interferon Alpha-2b in Participants With Chronic Hepatitis B and Elevated Alanine Aminotransferase (MK-4031-384)

Withdrawn
4
0
RoW
Tenofovir, Truvada, Pegylated interferon alpha-2b, SCH 054031, MK-4031
Merck Sharp & Dohme LLC
Hepatitis B
08/17
08/17

Download Options